Page 127 - Drug Class Review
P. 127
Drug Effectiveness Review Project
donepezil galantamine 67.2% 73.2% 15.6% 23.2% 9.4% 14.3% 4.7% 8.9% 0.0% 12.5% 6.3% 5.4% 3.1% 7.1% 1.6% 5.4% Post randomization exclusions: NR Open-label; only cognitive assessments were implemented by independent raters who were blinded to Overall loss to follow-up: 6.7% Loss to follow-up differential high: No donepezil galantamine 4.7% 8.9% 4.7% 7.1% Page 94 of 205
ITT: Yes patient assignment;
NR Yes NR N/A
Final Report Update 1 Authors: Jones et al. Year: 2004 ADVERSE EVENTS: Overall adverse effects reported: Nausea • Diarrhea • Anorexia • Vomiting • Headache • UTI • Dizziness • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
